Pan Cancer T Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 8

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 7

Pan Cancer T General Information

Description

Developer of T-cell therapies designed to provide treatment options for hard-to-treat solid cancers through adoptive therapy. The company's therapies are genetically engineered with TCRs to exploit the ability of the immune cells, to specifically and efficiently recognize and kill malignant cells according to the expression of intracellular target antigens, enabling patients to receive treatments to maximize the efficacy of TCR T-cells towards solid tumors.

Contact Information

Website
www.pancancer-t.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Marconistraat 16
  • 3029 AK Rotterdam
  • Netherlands
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Marconistraat 16
  • 3029 AK Rotterdam
  • Netherlands

Pan Cancer T Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Pan Cancer T Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Accelerator/Incubator 01-Jan-2025 Completed Startup
6. Later Stage VC 08-Dec-2025 Completed Pre-Clinical Trials
5. Early Stage VC (Series A) Cancelled Pre-Clinical Trials
4. Seed Round 11-Jul-2024 Completed Pre-Clinical Trials
3. Seed Round Completed Pre-Clinical Trials
2. Grant 11-Jan-2021 $1.1M Completed Pre-Clinical Trials
1. Spin-Off 01-Sep-2020 Completed Startup
To view Pan Cancer T’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Pan Cancer T Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of T-cell therapies designed to provide treatment options for hard-to-treat solid cancers through adoptive the
Drug Discovery
Rotterdam, Netherlands
8 As of 2024

Leiden, Netherlands
 

Oss, Netherlands
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Pan Cancer T Competitors (3)

One of Pan Cancer T’s 3 competitors is Ncardia, a Venture Capital-Backed company based in Leiden, Netherlands.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ncardia Venture Capital-Backed Leiden, Netherlands
Glycostem Therapeutics Private Equity-Backed Oss, Netherlands
CiMaas Venture Capital-Backed Maastricht, Netherlands
You’re viewing 3 of 3 competitors. Get the full list »

Pan Cancer T Patents

  • 4

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 4

    Pending

  • Expiring in next 12 mo

Pan Cancer T Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022209669-A1 T cells for use in therapy Pending 21-Jan-2021
AU-2022209669-A9 T cells for use in therapy Pending 21-Jan-2021
EP-4281469-A1 T cells for use in therapy Pending 21-Jan-2021
US-20240131155-A1 T cells for use in therapy Pending 21-Jan-2021 A61K40/11

Pan Cancer T Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Pan Cancer T Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Termeer Institute Accelerator/Incubator
InnovationQuarter Venture Capital Minority
Swanbridge Capital Venture Capital Minority
Thuja Capital Management Venture Capital Minority
Van Herk Groep Real Estate Minority
You’re viewing 5 of 7 investors. Get the full list »

Ready to get started?

Request a free trial

Pan Cancer T FAQs

  • When was Pan Cancer T founded?

    Pan Cancer T was founded in 2020.

  • Where is Pan Cancer T headquartered?

    Pan Cancer T is headquartered in Rotterdam, Netherlands.

  • What is the size of Pan Cancer T?

    Pan Cancer T has 8 total employees.

  • What industry is Pan Cancer T in?

    Pan Cancer T’s primary industry is Drug Discovery.

  • Is Pan Cancer T a private or public company?

    Pan Cancer T is a Private company.

  • What is Pan Cancer T’s current revenue?

    The current revenue for Pan Cancer T is .

  • How much funding has Pan Cancer T raised over time?

    Pan Cancer T has raised $22.4M.

  • Who are Pan Cancer T’s investors?

    Termeer Institute, InnovationQuarter, Swanbridge Capital, Thuja Capital Management, and Van Herk Groep are 5 of 7 investors who have invested in Pan Cancer T.

  • Who are Pan Cancer T’s competitors?

    Ncardia, Glycostem Therapeutics, and CiMaas are competitors of Pan Cancer T.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process